HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Myelofibrosis symptom control takes ‘significant’ step forward with ruxolitinib approval
-
- Diabetes drug reduced size, number of breast cancer stem cells
- Family history not a factor in rates of invasive disease, nodal involvement
- Higher level of education linked to decreased mortality rates for oral cavity, pharynx cancers
- Immunotherapy drug approval, efforts to target specific mutations highlight recent treatment
- Metastasis biopsy receptor status discordance may alter treatment plan
- Mood disorders did not further delay diagnostic resolution after abnormal mammograms
- Patients on long-term warfarin should have option for INR home monitoring Stephan Moll, MD
- Safety review of dabigatran under way
-
- Benefits of mammography are explained by biology, not dogma Laura Esserman, MD, MBA
- Obama administration plans increase in health IT usage to improve health care, create jobs
- The need for personalized information at the point of care William Wood, MD
- Bivalent vaccine had cross-protective effect against numerous HPV types
- Dose-intensive R-ACVBP improved survival, increased adverse effects in LBCL
- Plasma microRNA a diagnostic tool for early-stage liver cancer
- Salvage transplant safe, feasible for multiple myeloma
- Clodronate showed modest reduction of metastases in postmenopausal women
-
- Diabetes, obesity associated with development of breast cancer
- Everolimus improved PFS in patients with metastatic, ER-positive breast cancer
- Health insurance status affected likelihood of having reconstructive surgery after breast cancer
- Low-carbohydrate diet bested standard calorie restriction for lowering glucose levels, weight loss
- Pertuzumab improved PFS when given with trastuzumab, chemotherapy
- Potential new genetic biomarker linked to anti-myeloma activity of immune modulators
- SWOG-S0226: Drug combo performed better in treating hormone-sensitive breast cancer
- Trastuzumab improved long-term outcomes in obese patients with breast cancer
-
- Zoledronic acid improved DFS, OS in premenopausal women with breast cancer
- Denosumab viable therapy for preserving bone health of patients with cancer Lisa K. Lohr, PharmD, BCPS, BCOP